Pulmonx Corporation will announce its 2025 financial results on March 4, 2026, with a subsequent conference call.
Quiver AI Summary
Pulmonx Corporation, a leader in minimally invasive treatments for lung disease, announced it will release its financial results for the fourth quarter and full year of 2025 on March 4, 2026, after market close. Management will hold a conference call at 1:30 p.m. PT to discuss these results, with a live and archived webcast available on the company's website. Pulmonx is known for its innovative products, including the Zephyr® Endobronchial Valve, which is widely recognized as a standard treatment option for patients with severe emphysema and chronic obstructive pulmonary disease (COPD). The company has received FDA approval for its Zephyr Valve and has a significant international presence, further reinforcing its commitment to improving patient quality of life in the severe emphysema space.
Potential Positives
- Pulmonx Corporation is releasing its financial results for Q4 and full year 2025, indicating transparency and engagement with investors.
- The company is hosting a conference call to discuss these results, providing an opportunity for direct communication with stakeholders.
- The Zephyr® Endobronchial Valve has been recognized as a standard of care treatment option and is commercially available in more than 25 countries, showcasing Pulmonx's strong market presence and product acceptance.
- Pulmonx received FDA pre-market approval for the Zephyr Valve as a "breakthrough device," highlighting its innovative approach and the potential for future growth in the COPD treatment market.
Potential Negatives
- Announcement of financial results may indicate potential concerns about transparency or performance expectations if results are not favorable.
- Timing of the conference call after market close suggests the company might be anticipating significant market reaction.
- Absence of immediate financial performance details in the release could lead to speculation or uncertainty among investors.
FAQ
When will Pulmonx release its financial results?
Pulmonx will release financial results for the fourth quarter and full year of 2025 on March 4, 2026.
What time is the Pulmonx financial results conference call?
The conference call will begin at 1:30 p.m. PT / 4:30 p.m. ET on March 4, 2026.
How can I access the Pulmonx conference call?
The conference call will be available via a live and archived webcast on the 'Investors' section of the Pulmonx website.
What is Pulmonx Corporation known for?
Pulmonx Corporation is a leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD).
What is the Zephyr Valve and its significance?
The Zephyr Valve is a breakthrough device for treating severe emphysema and is considered a standard of care for improving patients' quality of life.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LUNG Insider Trading Activity
$LUNG insiders have traded $LUNG stock on the open market 23 times in the past 6 months. Of those trades, 0 have been purchases and 23 have been sales.
Here’s a breakdown of recent trading of $LUNG stock by insiders over the last 6 months:
- DANIEL P FLORIN sold 23,321 shares for an estimated $46,408
- DAVID AARON LEHMAN (GENERAL COUNSEL) has made 0 purchases and 8 sales selling 20,047 shares for an estimated $31,766.
- GEOFFREY BERAN ROSE (CHIEF COMMERCIAL OFFICER) has made 0 purchases and 8 sales selling 12,865 shares for an estimated $20,394.
- STEVEN S. WILLIAMSON (PRESIDENT AND CEO) has made 0 purchases and 2 sales selling 9,648 shares for an estimated $15,436.
- GLENDON E. III FRENCH (President and CEO) has made 0 purchases and 2 sales selling 8,805 shares for an estimated $13,823.
- MEHUL JOSHI (Chief Financial Officer & PAO) has made 0 purchases and 2 sales selling 7,936 shares for an estimated $12,697.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$LUNG Revenue
$LUNG had revenues of $21.5M in Q3 2025. This is an increase of 5.47% from the same period in the prior year.
You can track LUNG financials on Quiver Quantitative's LUNG stock page.
$LUNG Hedge Fund Activity
We have seen 48 institutional investors add shares of $LUNG stock to their portfolio, and 78 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 2,099,156 shares (-96.5%) from their portfolio in Q4 2025, for an estimated $4,639,134
- SOLEUS CAPITAL MANAGEMENT, L.P. added 2,038,323 shares (+inf%) to their portfolio in Q4 2025, for an estimated $4,504,693
- EXODUSPOINT CAPITAL MANAGEMENT, LP added 1,951,173 shares (+inf%) to their portfolio in Q4 2025, for an estimated $4,312,092
- DEERFIELD MANAGEMENT COMPANY, L.P. removed 1,890,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $3,061,800
- BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. removed 1,168,513 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,892,991
- KENT LAKE PR LLC added 926,157 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,500,374
- VESTAL POINT CAPITAL, LP removed 830,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $1,834,300
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$LUNG Analyst Ratings
Wall Street analysts have issued reports on $LUNG in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- D. Boral Capital issued a "Buy" rating on 11/13/2025
To track analyst ratings and price targets for $LUNG, check out Quiver Quantitative's $LUNG forecast page.
$LUNG Price Targets
Multiple analysts have issued price targets for $LUNG recently. We have seen 2 analysts offer price targets for $LUNG in the last 6 months, with a median target of $9.0.
Here are some recent targets:
- Jason Kolbert from D. Boral Capital set a target price of $14.0 on 11/13/2025
- Frank Takkinen from Lake Street set a target price of $4.0 on 10/28/2025
Full Release
REDWOOD CITY, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2025 after the close of trading on Wednesday, March 4, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/ .
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr
®
Endobronchial Valve, Chartis
®
Pulmonary Assessment System, LungTraX™ Platform, and StratX
®
Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit
www.Pulmonx.com
.
Pulmonx ® , AeriSeal ® , Chartis ® , StratX ® , and Zephyr ® are registered trademarks and LungTraX™ is a trademark of Pulmonx Corporation.
Contact
Brian Johnston
Laine Morgan
Gilmartin Group
[email protected]
